

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Vigonvita Life Sciences Co., Ltd.**

**蘇州旺山旺水生物醫藥股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2630)**

## **INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY**

This announcement is made by Vigonvita Life Sciences Co., Ltd. (the **“Company”**) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the **“Listing Rules”**) on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (《H 股公司境內未上市股份申請「全流通」業務指引》) promulgated by the China Securities Regulatory Commission (中國證券監督管理委員會) (the **“CSRC”**) on November 14, 2019 and further amended on August 10, 2023 (the **“Guidelines”**) regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

Pursuant to the Guidelines, the board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that on November 26, 2025, the Board has considered and approved the proposal for the implementation of the H share full circulation, which is to convert 100,220,667 unlisted shares of the Company (the **“Unlisted Shares”**) held by 10 shareholders of the Company (the **“Shareholders”**) into H shares of the Company (the **“H Shares”**) (representing approximately 59.7983% of the total issued shares of the Company as at the date of this announcement) (the **“H Share Full Circulation”**). Upon obtaining all the relevant approvals (including filing with the CSRC) and having complied with all the applicable laws, regulations and rules, 100,220,667 Unlisted Shares will be converted into H Shares, and the Company will also apply to the Stock Exchange for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the **“Conversion and Listing”**). Pursuant to the articles of association of the Company, no approval from the Shareholders at general meeting is required for the Conversion and Listing.

As at the date of this announcement, the Company has not submitted the application documents to the CSRC for the H Share Full Circulation. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements of the Listing Rules and/or the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as and when appropriate.

**The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Vigonvita Life Sciences Co., Ltd.**  
**Dr. Tian Guanghui**  
*Chairman of the Board, Executive Director,  
Chief Executive Officer and General Manager*

Hong Kong, November 27, 2025

*As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.*